Hamad Medical Corporation’s Department of Laboratory Medicine and Pathology announced an advanced phase of its Human Tissue Biobank with the Qatar Precision Health Institute on 7 October. The expansion includes storage and management of freshly resected biological tissue. HMC describes the capability as infrastructure for clinical care and biomedical research. The announcement gives no capacity target, project cost or timetable for the new phase.

Tissue biobanks preserve specimens and linked information under defined quality, governance and regulatory arrangements. HMC says the expanded service will maintain distinct pathways for clinical and research use. Research studies will continue to undergo ethical and regulatory review through HMC’s Medical Research Center. The announcement does not mean that stored material is automatically available to every researcher or for every proposed purpose.

HMC reported that the first phase currently holds at least 700,000 paraffin blocks and 2.6 million tissue slides. At least 250,000 of the slides are for immunohistochemistry. The corporation also said the first phase supported at least 58 research applications. That total includes approved projects and applications reviewed or still under review by HMC’s Medical Research Center; it should not be described as 58 approved or completed studies.

The earlier phase focused on formalin-fixed, paraffin-embedded tissue specimens. HMC says the ability to handle fresh tissue can support advanced molecular and genomic testing, next-generation sequencing and precision oncology programmes. These are uses described by the institution. The release reports no measured improvement in diagnostic accuracy or treatment outcomes for patients. Assessing the expansion’s effects will require operational and outcome data published later.

Separating clinical and research pathways means the same biobank infrastructure will serve two uses governed by distinct procedures. HMC says it will maintain informed consent, data privacy, specimen quality and existing ethical oversight. The collection of fresh tissue does not itself grant permission to conduct research. According to HMC, institutional review of research projects will continue, with the existing oversight system complementing the biobank.

The new phase links HMC’s work with QPHI to Qatar’s infrastructure for precision medicine and biomedical research. The release’s clearest measures are lower-bound counts from the first-phase collection and the number of applications it supported; they do not measure fresh-tissue throughput in the new phase, approved projects or patient access. Future institutional reporting on new specimens, clinical and research use, approved projects and research outputs would help assess how the added capability is being used.